Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12622000572763
Ethics application status
Approved
Date submitted
30/03/2022
Date registered
14/04/2022
Date last updated
16/03/2023
Date data sharing statement initially provided
14/04/2022
Type of registration
Prospectively registered

Titles & IDs
Public title
The effect of a Pasifika intervention on rates of rheumatic fever in South Auckland Pacific communities
Scientific title
The effect of a Pasifika intervention on rates of rheumatic fever in South Auckland Pacific communities
Secondary ID [1] 306502 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatic fever 325696 0
Condition category
Condition code
Inflammatory and Immune System 323048 323048 0 0
Autoimmune diseases
Infection 323268 323268 0 0
Other infectious diseases
Inflammatory and Immune System 323269 323269 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The aim of this study is to develop, design, implement and evaluate a new innovative intervention to reduce rheumatic fever for Pasifika communities in South Auckland.

This mixed-methods study utilises the Fa’afaletui paradigm. This is a Pacific centred methodology that enables discussion with a range of different and sometimes conflicting perspectives. A co-design approach will be utilised where the community participants and clinicians work together alongside researchers to develop a novel and innovative intervention to reduce the rheumatic fever burden impacting Pasifika communities. Phase two and three of the overall project outline the co-design, development, implementation, and evaluation of the intervention.

Phase 2: Designing the intervention and developing the implementation plan.
This will include a stocktake of programmes and interventions aimed at reducing rheumatic fever in NZ. This will occur as part of a scoping review to broadly identify the range of approaches used currently and in the past, where they have been implemented and whether they have been successful. Concise summaries of the scoping review results will be produced using a variety of techniques such as PowerPoint presentations, brochures, posters and storyboards. This will aid in informing workshop participants of what has been tried before, what has been successful and what might be useful for their co-designed intervention.

Approximately four day-long workshops will be conducted over a period of six months with PPHAG, PPBRN and other relevant Pasifika community members and stakeholders to explore their views of current and past rheumatic fever interventions and to co-design alternatives.

• The Pacific People’s Health Advisory Group (PPHAG): This group comprises male and female community members aged in their 20s to their 70s, of mixed Pasifika ethnicities (Samoan, Tongan, Niuean, Cook Islands) with a range of occupations, for example, nursing students, teachers, social workers, broadcasters and retirees.
• Pacific Practice-Based Research Network (PPBRN): All PBRN research officers (which include general practitioners, nurses, and receptionists depending on the practice) from South Auckland practices in the Network will be invited to participate in the workshops. Other practice staff members identified by PBRN research officers may also participate, should they wish to do so.
• Patients with rheumatic fever and their families: PPBRN practices will recruit Pacific patients diagnosed with rheumatic fever to test and evaluate the intervention. The invitation will also be extended to their extended family members who would like to participate. We will use purposive sampling aiming for a diversity of Pacific ethnicities, ages and other key characteristics of these participants.
• Other relevant stakeholders: Other stakeholders including community pharmacists, Primary Health Organisation (PHO) personnel, community members and/or others identified during the study may be invited to participate.

The workshops will be facilitated by six members from the Pacific Rheumatic Fever Project research team:
• 1 x Senior Lecturer with experience in Pacific community health, health promotion and community engagement.
• 2x General Practitioners with vast experience in teaching, general practice, and Pacific health research.
• 2x Research Fellows

Where possible, workshops will take place in-person (or virtually depending on pandemic restrictions) using cultural protocols and approaches. Dialogue within the workshops will follow Talanga, a Tongan participant-centred approach that means “interactive talking with a purpose” and enables empowering and interactive dialogue towards action.

Workshops will begin with short presentations of the current data trends and previous rheumatic fever interventions, such as the Ministry of Health's Rheumatic Fever Prevention Programme, community awareness strategies such as "Take it to Heart" run by Alliance Health Plus and school throat swabbing initiatives such as Mana Kidz. Participants will then collaboratively workshop innovative solutions using their expertise as members of the Pasifika community in South Auckland. Groups may be provided with large sheets of paper and whiteboards to brainstorm, and these data will be collected at the end of the workshop.

Once an intervention has been drafted, PPHAG, PPBRN and researchers will collectively refine it via further workshops. Expert reviewers will also contribute to this process to ensure that strategy is feasible and can be implemented in South Auckland. Factors to be addressed in the intervention include what components it entails (e.g. health promotion, education, prescribing, dispensing, patient reminders, family/whanau involvement), who leads it (eg doctor, nurse, pharmacist, team, community-led), and where it takes place (eg health premises, community location).

Implementation plan
To map the implementation of the final intervention, a framework will be developed using a logic model of change. This will outline the inputs (such as resources, personnel and funding required), activities (encompassing the tasks necessary for implementation), outputs (measures demonstrating implementation has occurred) and short-term outcomes (the expected changes).

Phase 3: Intervention implementation and Evaluation
The intervention will then be trialled in South Auckland and tested to see how well it works. It is anticipated that Phase 3 will start approximately six months after the conclusion of Phase 2 and implemented and evaluated over a 12 month period. Precise details of the evaluation will depend on the nature of the novel intervention and its characteristics.

Study approach
This phase will use an implementation science approach, which is a systematic study of the activities that facilitate the successful uptake of an evidence-based health intervention, in this case a strategy and programme to reduce rheumatic fever rates amongst Pasifika in South Auckland. The design of the evaluation of the intervention implementation will be underpinned by a theoretical framework and informed by behavioural change theory, whereby a person’s attitudes, personal or subjective norms and their perceived behaviour controls (not doing what they think is wrong) shape an individual’s behavioural intentions and hence their actual behaviours.
Intervention code [1] 323166 0
Prevention
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 330936 0
The incidence of Pacific Island acute rheumatic fever cases within the Counties Manukau District Health Board, by accessing District Health Board-collected incidence data.
Timepoint [1] 330936 0
3 months, 6 months and 12 months (primary endpoint) post-intervention commencement
Primary outcome [2] 330937 0
Hospitalisations in Auckland for first-episode acute rheumatic fever in Pacific people, accessed via hospitalisation data from the National Minimum Dataset.
Timepoint [2] 330937 0
6 months and 12 months (primary endpoint) post-intervention commencement
Secondary outcome [1] 408147 0
The acceptability of intervention delivery obtained via 5-point Likert scale surveys and semi-structured interviews with end-users.
Timepoint [1] 408147 0
6 months post-intervention commencement
Secondary outcome [2] 408476 0
Barriers and enablers of intervention delivery assessed using a semi-structured interviews with end-users.
Timepoint [2] 408476 0
6 months post-intervention commencement
Secondary outcome [3] 408673 0
The feasibility of the intervention as assessed via an audit of study enrolment logs to investigate recruitment and retention rates, the time required to recruit, adherence and rate of completion.
Timepoint [3] 408673 0
6 months post-intervention commencement

Eligibility
Key inclusion criteria
Pasifika patients, families and communities affected by rheumatic fever
Minimum age
11 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Participants aged <11 years
Participants who are not able to give to give consent or assent (where applicable).
Participants with a terminal or severe illness.

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/04/2024
Actual
Date of last participant enrolment
Anticipated
30/06/2024
Actual
Date of last data collection
Anticipated
30/06/2025
Actual
Sample size
Target
100
Accrual to date
Final
Recruitment outside Australia
Country [1] 24693 0
New Zealand
State/province [1] 24693 0
South Auckland

Funding & Sponsors
Funding source category [1] 310846 0
Charities/Societies/Foundations
Name [1] 310846 0
Royal Society Te Aparangi
Country [1] 310846 0
New Zealand
Primary sponsor type
Individual
Name
Dr Siobhan Tu'akoi
Address
Pacific Health section, School of Population Health
Faculty of Medical and Health Sciences
The University of Auckland
Bldg 507, Level 1, Room 1001
28 Park Avenue, Grafton
Auckland 1023
New Zealand
Country
New Zealand
Secondary sponsor category [1] 312101 0
Individual
Name [1] 312101 0
Dr Malakai 'Ofanoa
Address [1] 312101 0
Pacific Health section, School of Population Health
Faculty of Medical and Health Sciences
The University of Auckland
Bldg 507, Level B, Room B005
28 Park Avenue, Grafton
Auckland 1023
New Zealand
Country [1] 312101 0
New Zealand
Secondary sponsor category [2] 312485 0
Individual
Name [2] 312485 0
Professor Felicity Goodyear-Smith
Address [2] 312485 0
Department of General Practice and Primary Healthcare, School of Population Health
Faculty of Medical and Health Sciences
The University of Auckland
Bldg 507, Level 3, Room 3018
28 Park Avenue, Grafton
Auckland 1023
New Zealand
Country [2] 312485 0
New Zealand

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 310412 0
Auckland Health Research Ethics Committee
Ethics committee address [1] 310412 0
Ethics committee country [1] 310412 0
New Zealand
Date submitted for ethics approval [1] 310412 0
10/02/2022
Approval date [1] 310412 0
21/03/2022
Ethics approval number [1] 310412 0
AH23838

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 117570 0
Dr Siobhan Tu'akoi
Address 117570 0
Pacific Health section, School of Population Health
Faculty of Medical and Health Sciences
The University of Auckland
Bldg 507, Level 1, Room 1001
28 Park Avenue, Grafton
Auckland 1023
New Zealand
Country 117570 0
New Zealand
Phone 117570 0
+64 9 923 2368
Fax 117570 0
Email 117570 0
[email protected]
Contact person for public queries
Name 117571 0
Siobhan Tu'akoi
Address 117571 0
Pacific Health section, School of Population Health
Faculty of Medical and Health Sciences
The University of Auckland
Bldg 507, Level 1, Room 1001
28 Park Avenue, Grafton
Auckland 1023
New Zealand
Country 117571 0
New Zealand
Phone 117571 0
+64 9 923 2368
Fax 117571 0
Email 117571 0
[email protected]
Contact person for scientific queries
Name 117572 0
Felicity Goodyear-Smith
Address 117572 0
Department of General Practice and Primary Healthcare, School of Population Health
Faculty of Medical and Health Sciences
The University of Auckland
Bldg 507, Level 3, Room 3018
28 Park Avenue, Grafton
Auckland 1023
New Zealand
Country 117572 0
New Zealand
Phone 117572 0
+64 9 923 2357
Fax 117572 0
Email 117572 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
15619Study protocol    383628-(Uploaded-30-03-2022-07-49-29)-Study-related document.pdf
15620Informed consent form    383628-(Uploaded-30-03-2022-07-49-41)-Study-related document.pdf
15621Ethical approval    383628-(Uploaded-30-03-2022-07-49-48)-Study-related document.pdf



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
Dimensions AICo-designing an intervention to prevent rheumatic fever in Pacific People in South Auckland: a study protocol2022https://doi.org/10.1186/s12939-022-01701-9
N.B. These documents automatically identified may not have been verified by the study sponsor.